Altimmune announces positive topline results from 24-week (12-week extension) trial of pemvidutide in subjects with non-alcoholic fatty liver disease (nafld)

Gaithersburg, md., dec. 20, 2022 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with nafld.

ALT Ratings Summary

ALT Quant Ranking